<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477267</url>
  </required_header>
  <id_info>
    <org_study_id>INS009-15-033</org_study_id>
    <nct_id>NCT02477267</nct_id>
  </id_info>
  <brief_title>Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers</brief_title>
  <official_title>A Pivotal, Phase 1, Open-Label, Randomized, Crossover, Single-Dose, Comparative Bioavailability Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>INSYS Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>INSYS Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the bioavailability of a test formulation
      of Buprenorphine Naloxone Sublingual (SL) spray to that of a single dose of Suboxone®
      (buprenorphine and naloxone) sublingual film, under fasted conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>within 21 days</time_frame>
    <description>Categories: buprenorphine, norbuprenorphine, unconjugated naloxone, and total naloxone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>within 21 days</time_frame>
    <description>Categories: buprenorphine, norbuprenorphine, unconjugated naloxone, and total naloxone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination rate constant</measure>
    <time_frame>within 21 days</time_frame>
    <description>Categories: buprenorphine, norbuprenorphine, unconjugated naloxone, and total naloxone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (T½)</measure>
    <time_frame>within 21 days</time_frame>
    <description>Categories: buprenorphine, norbuprenorphine, unconjugated naloxone, and total naloxone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve to the final sample with a concentration greater than the limit of quantification (LOQ [AUClast])</measure>
    <time_frame>within 21 days</time_frame>
    <description>Categories: buprenorphine, norbuprenorphine, unconjugated naloxone, and total naloxone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve extrapolated to infinity (AUCinf)</measure>
    <time_frame>within 21 days</time_frame>
    <description>Categories: buprenorphine, norbuprenorphine, unconjugated naloxone, and total naloxone</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Opiate Dependence</condition>
  <arm_group>
    <arm_group_label>Test-Reference Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SL spray, followed by SL film</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference-Test Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SL film followed by SL spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL spray</intervention_name>
    <arm_group_label>Test-Reference Sequence</arm_group_label>
    <arm_group_label>Reference-Test Sequence</arm_group_label>
    <other_name>Buprenorphine naloxone sublingual spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL film</intervention_name>
    <arm_group_label>Test-Reference Sequence</arm_group_label>
    <arm_group_label>Reference-Test Sequence</arm_group_label>
    <other_name>Buprenorphine and naloxone sublingual film</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets protocol-specified criteria for qualification and contraception

          -  Is willing and able to remain confined in the study unit for the entire duration of
             each treatment period and comply with restrictions related food, drink and medications

          -  Voluntarily consents to participate and provides written informed consent prior to any
             protocol-specific procedures

        Exclusion Criteria:

          -  Has history or current use of over-the-counter medications, dietary supplements, or
             drugs (including nicotine and alcohol) outside protocol-specified parameters

          -  Has signs, symptoms or history of any condition that, per protocol or in the opinion
             of the investigator, might compromise:

               1. the safety or well-being of the participant or study staff;

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding);

               3. the analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni DeCastro</last_name>
    <role>Study Director</role>
    <affiliation>INSYS Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials Early Phase Services, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2015</study_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

